Incite Health, Inc. Introduces Pharmacogenomics Services to Improve the Safety, Efficacy, and Efficiency of Clinical Trials

New innovative clinical services to help pharmaceutical and biotech companies improve patient recruitment, reduce the risk of adverse reactions, and refine the drug development process.

DOYLESTOWN, Pa., November 14, 2023 (Newswire.com) - Incite Health, Inc., a CLIA-certified, CAP-accredited, high-complexity Contract Research Organization, announces the expansion of its services with the launch of its pharmacogenomics platform to support the drug development initiatives of its pharmaceutical and biotech partners. 

Pharmacogenomics, also known as PGx, is a specialized type of genetic testing that examines how an individual’s genetic makeup influences their response to medications.

By utilizing Incite Health’s PGx services, drug development leaders will be able to improve the safety of clinical trials by identifying those potential participants who, based on their unique genetic profile, may have an increased chance of experiencing a negative reaction to the new drug.  Additionally, researchers will be able to tailor dosages, formulations, and treatment plans based on genetic responses and identify patients with specific genetic profiles that match their drug’s mechanism of action.

This service will allow pharmaceutical and biotech companies to improve patient recruitment efficiency, optimize the drug development process, accelerate clinical trial timelines, and reduce overall drug development costs. 

Renold J. Capocasale, Founder & CEO of Incite Health, Inc., stated, “Incite Health is committed to utilizing the power of genomics and precision medicine to improve patients’ lives and we are excited to offer these innovative pharmacogenomics services to our pharmaceutical and biotech partners.”  

Incite Health offers both off-the-shelf core panels as well as the ability to create customized panels to meet the specific needs of any clinical trial. The highly complex PGx data created by Incite Health is distilled into comprehensive and easy-to-review reports. The detailed reports provide actionable recommendations and incorporate all the latest guidelines from the Clinical Pharmacogenomics Implementation Consortium (CPIC).  

About Incite Health, Inc. 

Incite Health, Inc. is a multidisciplined, high-complexity, clinical laboratory helping revolutionize clinical decision-making by providing insightful and actionable solutions through state-of-the-art methodologies. Our data-driven approach supports early diagnosis, disease monitoring, and precision medicine, leading to more effective interventions that ultimately improve patient lives.

For more information, please contact Connie Scotese at cscotese@incitehealth.com or (610) 304-2840.

Visit us at www.incitehealth.com

Contact Information:
John Healey
President
jhealey@incitehealth.com
609 613 3943


Original Source: Incite Health, Inc. Introduces Pharmacogenomics Services to Improve the Safety, Efficacy, and Efficiency of Clinical Trials